Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Pagani, Olivia; M. Regan, Meredith; Walley, Barbara; F. Fleming, Gini; Colleoni, Marco; Láng, István; Gómez, Henry; Tondini, Carlo; J. Burstein, Harold; A. Perez, Edith; Ciruelos, Eva; Stearns, Vered; Bonnefoi, Hervé; Martino, Silvana; E. Geyer, Charles; Pinotti, Graziella; Puglisi, Fabio; Crivellari, Diana; Ruhstaller, Thomas; P. Winer, Eric; Rabaglio, Manuela; Maibach, Rudolf; Ruepp, Barbara; Giobbie‐Hurder, Anita; N. Price, Karen; Bernhard, Jürg; Luo, Weixiu; Ribi, Karin; Viale, Giuseppe; S. Coates, Alan; D. Gelber, Richard; Goldhirsch, Aron; A. Francis, Prudence

doi:10.1056/nejmoa1404037

Public

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Published in New England Journal of Medicine • Jun 1, 2014

Authors:

Olivia Pagani

Meredith M. Regan

Barbara Walley

Abstract

BACKGROUND: Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive breast cancer. METHODS: In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive early breast cancer to...

Subject

Medicine

Exemestane

Adjuvant

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!